2026 NPPES data Otolaryngology Physician NPI 1649254525
Verify on CMS →

MARK CARDAMONE-RAYNER

Otolaryngology Physician in MANKATO, Minnesota. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
334
Medicare Part D claims · 111 beneficiaries · Otolaryngology Physician avg: 509
Generic prescribing
91%
generic claims · 9% brand-name · higher generic rates reduce patient out-of-pocket costs
Industry payments
$58.52
4 payments · CMS Open Payments (Sunshine Act)
What the federal data reveals: MARK CARDAMONE-RAYNER is a Otolaryngology Physician ([object Object]) practicing in MANKATO, Minnesota with a Medicare Part D prescribing footprint of 334 claims across 111 beneficiaries — 9% brand-name prescribing . Industry payments of $58.52 across 4 transactions are disclosed under CMS Open Payments (Sunshine Act).

What stands out: MARK CARDAMONE-RAYNER filed 334 Medicare Part D claims in 2023 across MANKATO, Minnesota. Every figure on this page comes straight from federal CMS records, with no proprietary rating applied.

Board certification likely (heuristic — not verified)

MARK CARDAMONE-RAYNER practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + 1 hospital affiliation — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).

MARK CARDAMONE-RAYNER at a glance

Quality data not reported

NPI registry status

Active

Issued 12/03/2005

NPI 1649254525

Primary specialty

Otolaryngology Physician

Mid-sized

10,895 US NPIs in this specialty

Medicare Part D claims

334 34% vs specialty avg

2023 prescription claims

Specialty avg: 509

Specialty distribution in Minnesota

How Otolaryngology Physician compares to other specialties among Minnesota providers

Minnesota providers

Otolaryngology Physician share within Minnesota

1. Otolaryngology Physician42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Otolaryngology Physician share within Minnesota

Specialty board-certification context

Estimated specialty board-certified rate — Otolaryngology Physician (ABMS / AOA reference)

Quality data not reported
Est. board-certified rate
78%
Otolaryngology Physician ABMS/AOA estimate

Est. board-certified rate (Otolaryngology Physician) — ABMS / AOA estimate

0%100%78%
Est. board-certified rate (Otolaryngology Physician) — ABMS / AOA estimate

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

MARK CARDAMONE-RAYNER is a Otolaryngology Physician provider practicing in MANKATO, Minnesota, according to the CMS National Plan and Provider Enumeration System (NPPES). NPI: 1649254525. This profile includes practice location, specialty classification, and organizational affiliations from the CMS provider registry. Provider information is self-reported to CMS and updated monthly.

MARK CARDAMONE-RAYNER appears in the CMS NPPES registry as a Otolaryngology Physician provider at 1015 MARSH ST, MANKATO, MN, 56001, with a listed phone of (507) 389-4700. NPI 1649254525 was issued on 12/03/2005. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what CARDAMONE-RAYNER most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 334 prescription claims written by this provider, covering 111 Medicare beneficiaries and totaling roughly $62K in drug spend, split 9% brand-name and 91% generic by claim count, with an opioid prescribing rate of 5.7%. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy.

Otolaryngology Physician is a mid-sized specialty nationwide, with 10,895 enrolled providers across 54 states and an average of 509 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

1015 MARSH ST
MANKATO, MN 56001

Provider Details

NPI 1649254525
Specialty Otolaryngology Physician
Gender Male
NPI Issued 12/03/2005

Hospital and facility affiliations

Facilities where MARK CARDAMONE-RAYNER bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" — a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.

SCHOOLCRAFT MEMORIAL HOSPITAL
MANISTIQUE, MI
Critical Access Hospitals
CMS CCN: 231303

Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).

Industry payments received (2024) — CMS Open Payments transparency data

The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for MARK CARDAMONE-RAYNER. Source: openpaymentsdata.cms.gov.

Total received

$59

Largest payer

Merck Sharp & Dohme LLC

Most common payment type

Food and Beverage

Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.

Brand vs generic prescribing mix · Generic-heavy

MARK CARDAMONE-RAYNER — brand share 9.0%
Specialty average (est.)

9% brand-name claims vs 91% generic, on 334 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

334
Total Claims
$62K
Total Drug Cost
111
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
382
Total Day Supply
8,301
Brand vs Generic
9% brand / 91% generic
Brand Drug Cost
$55K
Generic Drug Cost
$7K
Opioid Claims
19 (5.7% rate)
Antibiotic Claims
30

Patient Demographics

Average Patient Age
73.0 years
Avg HCC Risk Score
1.16
Gender Split
58% female / 42% male
Age Distribution
<65: 13, 65-74: 48, 75-84: 36, 85+: 14

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

Drug Claims
Fluticasone Propionate
48
Famotidine
38
Ciprofloxacin-Dexamethasone
Ciprofloxacin Hcl/Dexameth
25
Levothyroxine Sodium
21
Omeprazole
18
Prednisone
18
Oxycodone-Acetaminophen
Oxycodone Hcl/Acetaminophen
15
Dupixent Pen
Dupilumab
14
Fluocinolone Acetonide Oil
13

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Otolaryngology Physician Overview

How MARK CARDAMONE-RAYNER fits within the Otolaryngology Physician landscape nationally.

10,895
Otolaryngology Physician Providers in US
54
States with Otolaryngology Physician
509
Avg Claims per Provider

MARK CARDAMONE-RAYNER's 334 claims are below the specialty average of 509.

Nearby Otolaryngology Physician Providers in Minnesota

Other clinicians with the same primary specialty enrolled in Minnesota, drawn from the same CMS NPPES roster as CARDAMONE-RAYNER.

Compare Otolaryngology Physician nationally: see state-by-state distribution →

Frequently Asked Questions

What is MARK CARDAMONE-RAYNER's specialty?
MARK CARDAMONE-RAYNER specializes in Otolaryngology Physician and practices in MANKATO, Minnesota.
How much does MARK CARDAMONE-RAYNER prescribe under Medicare Part D?
In 2023, MARK CARDAMONE-RAYNER wrote 334 Medicare Part D claims totaling $62K in drug costs for 111 beneficiaries.
Where is MARK CARDAMONE-RAYNER located?
MARK CARDAMONE-RAYNER is located at 1015 MARSH ST, MANKATO, MN, 56001. Phone: (507) 389-4700.
What is MARK CARDAMONE-RAYNER's NPI number?
MARK CARDAMONE-RAYNER's National Provider Identifier (NPI) is 1649254525, issued on 12/03/2005.
Does MARK CARDAMONE-RAYNER prescribe more brand-name or generic drugs?
MARK CARDAMONE-RAYNER's prescribing is 9% brand-name and 91% generic drugs by claim count, with $55K in brand drug costs.
Does MARK CARDAMONE-RAYNER prescribe opioids?
Yes, MARK CARDAMONE-RAYNER had 19 opioid claims in 2023 with an opioid prescribing rate of 5.7%.
How many Otolaryngology Physician providers are there in the US?
There are 10,895 Otolaryngology Physician providers across 54 states in the US. The average Otolaryngology Physician provider writes 509 Medicare Part D claims per year.
What drugs does MARK CARDAMONE-RAYNER prescribe most often?
Based on 2023 Medicare Part D data, MARK CARDAMONE-RAYNER's most frequently prescribed drugs include Fluticasone Propionate, Famotidine, Ciprofloxacin-Dexamethasone. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does MARK CARDAMONE-RAYNER accept Medicare?
MARK CARDAMONE-RAYNER appears in CMS Medicare data with 334 Part D claims and 111 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify MARK CARDAMONE-RAYNER's credentials?
MARK CARDAMONE-RAYNER's NPI is 1649254525. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology